Want to join the conversation?
$PFE said that as per its agreement with RPI, a subsidiary of Royalty Pharma, RPI will fund up to $300MM in development costs related to certain Phase III clinical trials of $PFE's breast cancer drug Ibrance. For up to 3 years post Hospira acquisition, $PFE expects costs to be $1Bil, excluding costs of $215MM in 2015 for in-process R&D rights.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?